Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.

Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, Hale G, Etuk A, Wilson M, Adams S, Veys P, van Kesteren C, Bredius RGM.

Clin Pharmacokinet. 2019 May 27. doi: 10.1007/s40262-019-00782-0. [Epub ahead of print]

PMID:
31131436
2.

No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.

Schoemakers RJ, van Kesteren C, van Rosmalen J, Eussen MLJM, Dieleman HG, Beex-Oosterhuis MM.

J Child Adolesc Psychopharmacol. 2019 Apr;29(3):192-196. doi: 10.1089/cap.2018.0111. Epub 2019 Jan 23.

PMID:
30672720
3.

Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation.

de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, Boelens JJ.

Biol Blood Marrow Transplant. 2019 Apr;25(4):819-826. doi: 10.1016/j.bbmt.2018.10.013. Epub 2018 Oct 23.

PMID:
30359735
4.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, van Kesteren C, Huitema ADR.

Clin Pharmacokinet. 2019 May;58(5):627-637. doi: 10.1007/s40262-018-0715-9.

5.

Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.

Punt AM, Langenhorst JB, Egas AC, Boelens JJ, van Kesteren C, van Maarseveen EM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jun 15;1055-1056:81-85. doi: 10.1016/j.jchromb.2017.04.025. Epub 2017 Apr 15.

6.

Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies.

van Kesteren CF, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, Kahn RS, Sommer IE.

Transl Psychiatry. 2017 Mar 28;7(3):e1075. doi: 10.1038/tp.2017.4.

7.

Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.

Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, Belitser SV, Bredius RGM, Raymakers RAP, Knibbe CAJ, Minnema MC, van Kesteren C, Kuball J, Boelens JJ.

Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7. Epub 2017 Mar 16. Erratum in: Lancet Haematol. 2017 May;4(5):e201.

PMID:
28330607
8.

Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation.

Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, Boelens JJ.

Blood. 2016 Dec 8;128(23):2734-2741. Epub 2016 Oct 4.

9.

Antithymocyte globulin: Importance of good clinical pharmacological practice.

Admiraal R, van Kesteren C, Nierkens S, Boelens JJ.

J Allergy Clin Immunol. 2016 Aug;138(2):633. doi: 10.1016/j.jaci.2016.02.036. Epub 2016 May 20. No abstract available.

PMID:
27212085
10.

Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, van Tol MJ, Knibbe CA, Bredius RG, Boelens JJ.

Lancet Haematol. 2015 May;2(5):e194-203. doi: 10.1016/S2352-3026(15)00045-9. Epub 2015 Apr 21.

PMID:
26688094
11.

[Auditory verbal hallucinations in an adult with autism spectrum disorder].

Malgaz M, van Kesteren CF, Sommer IE.

Tijdschr Psychiatr. 2015;57(9):684-7. Dutch.

12.

Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.

Willemsen L, Jol-van der Zijde CM, Admiraal R, Putter H, Jansen-Hoogendijk AM, Ostaijen-Ten Dam MM, Wijnen JT, van Kesteren C, Waaijer JL, Lankester AC, Bredius RG, van Tol MJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82. doi: 10.1016/j.bbmt.2014.11.674. Epub 2014 Dec 5.

13.

Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.

Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA.

Clin Pharmacokinet. 2015 Apr;54(4):435-46. doi: 10.1007/s40262-014-0214-6.

PMID:
25466602
14.

Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.

Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA.

Arch Dis Child. 2014 Mar;99(3):267-72. doi: 10.1136/archdischild-2013-303721. Epub 2013 Dec 19.

PMID:
24356807
15.

Predictive performance of a busulfan pharmacokinetic model in children and young adults.

Bartelink IH, van Kesteren C, Boelens JJ, Egberts TC, Bierings MB, Cuvelier GD, Wynn RF, Slatter MA, Chiesa R, Danhof M, Knibbe CA.

Ther Drug Monit. 2012 Oct;34(5):574-83.

PMID:
22972539
16.

A prospective randomized clinical study of changes in soft tissue position following immediate and delayed implant placement.

van Kesteren CJ, Schoolfield J, West J, Oates T.

Int J Oral Maxillofac Implants. 2010 May-Jun;25(3):562-70.

PMID:
20556256
17.

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.

Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98.

18.

Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia.

van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM.

Ther Drug Monit. 2006 Jun;28(3):339-44.

PMID:
16778717
19.

Development of an optimal lidocaine infusion strategy for neonatal seizures.

Malingré MM, Van Rooij LG, Rademaker CM, Toet MC, Ververs TF, van Kesteren C, de Vries LS.

Eur J Pediatr. 2006 Sep;165(9):598-604. Epub 2006 May 12.

PMID:
16691409
20.

70th Scientific Sessions of the American Heart Association.

Jan Danser AH, van Kesteren CA, MaassenVanDenbrink A.

Expert Opin Investig Drugs. 1998 Jan;7(1):117-20.

PMID:
15991925
21.

Alcohol swabs and venipuncture in a routine hospital setting: no effect on blood ethanol measurement.

Malingré M, Ververs T, Bos S, van Kesteren C, van Rijn H.

Ther Drug Monit. 2005 Jun;27(3):403-4. No abstract available.

PMID:
15905814
22.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH.

Invest New Drugs. 2005 Jun;23(3):225-34.

PMID:
15868378
23.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

van Kesteren Ch, de Vooght MM, López-Lázaro L, Mathôt RA, Schellens JH, Jimeno JM, Beijnen JH.

Anticancer Drugs. 2003 Aug;14(7):487-502. Review.

PMID:
12960733
24.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A.

Eur J Cancer. 2003 Sep;39(13):1842-51.

PMID:
12932661
25.

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH.

Invest New Drugs. 2003 May;21(2):225-41. Review.

PMID:
12889741
26.

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH; Early Clinical Studies Group of the EORTC and NDDO Oncology.

Br J Clin Pharmacol. 2002 Nov;54(5):463-71.

27.

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

Van Kesteren C, Beijnen JH, Schellens JH.

Anticancer Drugs. 2002 Nov;13(10):989-97. Review.

PMID:
12439332
28.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2002 Oct 1;20(19):4065-73.

PMID:
12351604
29.

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.

Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schellens JH, ten Bokkel Huinink WW.

Br J Cancer. 2002 Sep 9;87(6):608-14.

30.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH.

Anticancer Drugs. 2002 Apr;13(4):381-93.

PMID:
11984084
31.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK.

Clin Cancer Res. 2002 Jan;8(1):75-85.

32.

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.

van Kesteren C, Mathĵt RA, López-Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.

Cancer Chemother Pharmacol. 2001 Dec;48(6):459-66.

PMID:
11800026
33.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

Sparidans RW, Rosing H, Hillebrand MJ, López-Lázaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E, van Oosterom AT, Schellens JH, Beijnen JH.

Anticancer Drugs. 2001 Sep;12(8):653-66.

PMID:
11604552
34.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

van Kesteren C, Cvitkovic E, Taamma A, López-Lázaro L, Jimeno JM, Guzman C, Math t RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.

Clin Cancer Res. 2000 Dec;6(12):4725-32.

35.

Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II.

van Kesteren CA, Saris JJ, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA, Danser AH.

Cardiovasc Res. 1999 Jul;43(1):148-56.

PMID:
10536699
36.

Uptake and proteolytic activation of prorenin by cultured human endothelial cells.

Admiraal PJ, van Kesteren CA, Danser AH, Derkx FH, Sluiter W, Schalekamp MA.

J Hypertens. 1999 May;17(5):621-9.

PMID:
10403605
37.

Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells.

van Kesteren CA, Danser AH, Derkx FH, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA.

Hypertension. 1997 Dec;30(6):1389-96.

PMID:
9403558
38.

Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts.

van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA, Danser AH.

J Mol Cell Cardiol. 1997 Aug;29(8):2147-57.

PMID:
9281446
39.

Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding.

Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA.

Circulation. 1997 Jul 1;96(1):220-6.

PMID:
9236437
40.

69th scientific sessions of the American Heart Association.

Danser AH, MaassenVanDenBrink A, van Kesteren CA.

Expert Opin Investig Drugs. 1997 Jan;6(1):87-90.

PMID:
15989565

Supplemental Content

Loading ...
Support Center